Biotech entity
Source depth averages 2 original sources per story, versus 3.9 across the same-window beat baseline. US FDA is most often covered alongside AH-008, which appears in 1 of these 4 stories. Across a 147-day span, the pace is roughly 0.2 stories per week.
Last mentioned: Jul 29, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Source depth averages 2 original sources per story, versus 3.9 across the same-window beat baseline. US FDA is most often covered alongside AH-008, which appears in 1 of these 4 stories. Across a 147-day span, the pace is roughly 0.2 stories per week. Their average consequence score of 6.8 runs above the beat's 6.3 for that window. Coverage clusters in clinical-trial, which accounts for 2 of those 4, with the remainder spread across 1 other category. We currently track 4 Biotech stories that mention US FDA, published between March 5, 2026 and July 29, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 475 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering US FDA. Shared-story counts are live from our verified record — not editorial picks.
Data Readout
Anticipated preliminary safety and pharmacokinetic results from Phase I.
Trial Initiation
Expected commencement of patient recruitment and site activation.
FDA IND Approval
GNTbm receives official clearance to begin Phase I trials for GNTbm-38.
Following FDA 510(k) clearance, Navi Medical Technologies raises $6.8M to advance its Neonav ECG-based catheter placement system for neonates, with clinical evaluations underway at two leading US children's hospitals.
Source: manilatimes.net · sydneysun.com
AnHorn Medicines’ neuroprotective candidate AH-008 cleared FDA IND and received Taiwan CDE Index Case status, advancing into human trials for chemotherapy-induced peripheral neuropathy, a condition with zero approved preventive therapies.
Source: prnewswire.com
In a preclinical MOU, HanchorBio will evaluate its CD47/SIRPα asset HCB101 alongside InxMed’s ifebemtinib and OMTX705. The partnership signals a strategic pivot toward using HCB101 as a combination backbone, potentially de-risking the single-indication pipeline and differentiating the asset in a tricky class.
Source: manilatimes.net · prnewswire.com
GNTbm has received Investigational New Drug (IND) approval from the U.S. FDA to initiate Phase I clinical trials for its self-developed anti-cancer therapy, GNTbm-38. This milestone marks the company's formal entry into the U.S. clinical landscape, targeting advanced malignancies with its proprietary therapeutic candidate.
US FDA is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
